Carbamic acid, [2-(1-pyrrolidinyl)ethyl]- | 875819-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-
• 英文别名: (2-(Pyrrolidin-1-yl)ethyl)carbamic acid；2-pyrrolidin-1-ylethylcarbamic acid
• CAS: 875819-87-7
• 化学式: C₇H₁₄N₂O₂
• 分子量: 158.2
• InChiKey: FDWCSUNGKNOYDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] AROMATIC AMIDES AND USES THEREOF<br/>[FR] AMIDES AROMATIQUES ET LEURS UTILISATIONS
  申请人：BIOTA SCIENT MANAGEMENT

  公开号：WO2012142671A1

  公开（公告）日：2012-10-26

  The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

  本发明提供了化合物的结构式(I)：以及它们的盐、消旋体、异构体、对映异构体、立体异构体、水合物、溶剂合物、N-氧化物、药学上可接受的衍生物或前药。还提供了这些化合物作为抗菌剂的用途，包括它们的组合物和制造过程。
• [EN] CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS<br/>[FR] CERTAINES ENTITÉS CHIMIQUES, COMPOSITIONS, ET PROCÉDÉS ASSOCIÉS
  申请人：SUZHOU NEUPHARMA CO LTD

  公开号：WO2011085641A1

  公开（公告）日：2011-07-21

  Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.

  描述了一种是不法林衍生物的化学实体、制药组合物和治疗癌症的方法。
• UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE
  申请人：GENZYME CORPORATION

  公开号：US20200102324A1

  公开（公告）日：2020-04-02

  Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

  本文描述了一种化合物，其化学式为（I），以及其药用盐。本文还描述了这些组合物以及在治疗各种疾病和症状的方法中使用这些组合物，特别是克拉贝氏病（KD）和间染色质白质脑病（MLD）。
• [EN] CALCIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS DE CANAUX CALCIQUES
  申请人：CAVION INC

  公开号：WO2018152317A1

  公开（公告）日：2018-08-23

  The present disclosure describes carbamate analogs of mibefradil, as well as their compositions and methods of use. The compounds block the activity of one or more isoforms of voltage-gated calcium channels and are useful in the treatment of diseases including, e.g., cancer.

  本公开描述了米贝非特地的氨甲酸酯类似物，以及它们的组成和使用方法。这些化合物阻断了一个或多个电压门控钙通道的活性，并可用于治疗包括癌症在内的疾病。
• [EN] SYNTHESIS AND USE OF AMINO LIPIDS<br/>[FR] SYNTHÈSE ET UTILISATION DE LIPIDES AMINÉS
  申请人：INCELLA GMBH

  公开号：WO2016005318A1

  公开（公告）日：2016-01-14

  The present invention provides novel amino lipids and a method for synthesizing these compounds. According to the invention, the amino lipids have a structure of the following formula (I) wherein Z is either hydrogen or -X1 R1, R1 and R2 are the same or different and independently C6-C24 alkyl, C6-C24 alkenyl, C6-C24 alkynyl, or C6-C24 acyl, which can be optionally substituted with a C1-C6 hydrocarbyl group, X1 and X2 are the same or different, either S or S=O or S(=O)2, Y is either (II) or heterocycles of the formula (III) or (IV) wherein k and I are integers from 0 to 2, R3 and R4 are either the same or different and independently C1-C12 alkyl, C1-C12 alkenyl, or C1-C12 alkynyl, wherein alkyl, alkenyl or alkynyl may be optionally substituted with a C1-C6 hydrocarbyl group, or R3 and R4 optionally join to form, together with the nitrogen atom to which they are bound, an optionally substituted N-heterocyclic ring of 3 to 10 atoms comprising 1 to 7 nitrogen atoms, or R3 and R4 are the same or different alkyl amines; R5 and R6 are either absent or is hydrogen or C1-C12 alkyl to provide a quaternary amine, R7 is either hydrogen or C1-C12 alkyl, m is an integer from 1 to 12, n is an integer from 1 to 12, and p is an integer from 1 to 3, wherein preferably Y = N for p = 2 or 3.

  本发明提供了新型氨基脂质和合成这些化合物的方法。根据本发明，氨基脂质具有以下式（I）的结构，其中Z为氢或-X1 R1，R1和R2相同或不同，独立为C6-C24烷基，C6-C24烯基，C6-C24炔基或C6-C24酰基，可选择地取代为C1-C6烃基团，X1和X2相同或不同，为S或S=O或S(=O)2，Y为（II）或式（III）或（IV）的杂环，其中k和l为0至2的整数，R3和R4相同或不同，独立为C1-C12烷基，C1-C12烯基或C1-C12炔基，其中烷基，烯基或炔基可选择地取代为C1-C6烃基团，或R3和R4可选择地结合，与它们所结合的氮原子一起形成，可选择地取代的含有1至7个氮原子的3至10个原子的N-杂环，或R3和R4为相同或不同的烷基胺；R5和R6要么不存在，要么为氢或C1-C12烷基以提供季铵盐，R7要么为氢，要么为C1-C12烷基，m为1至12的整数，n为1至12的整数，p为1至3的整数，其中最好是Y = N，当p = 2或3时。